My ePortfolio Register   

SABCS 2017 /
Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.17
Views: 164
Rating:

Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Loi speaks at a SABCS 2017 press session about data presented from the phase Ib/II PANACEA trial.

She describes how a combination of pembrolizumab and trastuzumab, tested in patients with trastuzumab-resistant advanced HER2-positive breast cancer, was well tolerated and had clinical benefit in patients whose tumors were positive for a biomarker for pembrolizumab.

Read the news story for more. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence